The role of HDAC6 in Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 33, Issue 2, 2013, Pages 283-295

  Zhang, Ling ^a   Sheng, Shuli ^a   Qin, Chuan ^a  

^a INSTITUTE OF LABORATORY ANIMAL SCIENCE   (China)

Author keywords

Alzheimer's disease; autophagy; deacetylation; histone deacetylase 6 (HDAC6); neurodegeneration

Indexed keywords

ALPHA TUBULIN; BRAIN DERIVED NEUROTROPHIC FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; KU ANTIGEN; TAR DNA BINDING PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ASTROCYTE; BRAIN REGION; CELL FUNCTION; CELL TRANSPORT; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME ACTIVITY; ENZYME STRUCTURE; EPIGENETICS; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; HIPPOCAMPUS; HISTONE ACETYLATION; HUMAN; IMMUNE RESPONSE; IMMUNITY; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVE FIBER GROWTH; NERVE FIBER TRANSPORT; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PREVALENCE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN UNFOLDING; REVIEW; RNA PROCESSING; TRAUMATIC BRAIN INJURY;

EID: 84872458837     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-120727     Document Type: Review

References (96)

1. D'Mello SR (2009) Histone deacetylases as targets for the treatment of human neurodegenerative diseases. Drug News Perspect 22, 513-524.
2. Li G, Jiang H, Chang M, Xie H, Hu L (2011) HDAC6 -tubulin deacetylase: A potential therapeutic target in neurodegenerative diseases. J Neurosci 304, 1-8.
3. Fischer A, Sananbenesi F, Mungenast A, Tsai LH (2010) Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol Sci 31, 605-617.
4. Du G, Jiao R (2011) To prevent neurodegeneration: HDAC6 uses different strategies for different challenges. Commun Integr Biol 4, 139-142.
5. d'Ydewalle C, Bogaert E, Van Den Bosch L (2012) HDAC6 at the intersection of neuroprotection and neurodegeneration. Traffic 13, 771-719.
6. Yang XJ, Gregoire S (2005) Class II histone deacetylases: From sequence to function, regulation, and clinical implication. Mol Cell Biol 25, 2873-2884. (Pubitemid 40464294)
7. Valenzuela-Fernandez A, Cabrero JR, Serrador JM, Sanchez-Madrid F (2008) HDAC6: A key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends Cell Biol 18, 291-297.
8. Boyault C, Zhang Y, Fritah S, Caron C, Gilquin B, Kwon SH, Garrido C, Yao TP, Vourc'h C, Matthias P, Khochbin S (2007) HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev 21, 2172-2181. (Pubitemid 47360839)
9. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP (2003) The deacetylase HDAC6 regulates aggresome formation and cell viability in response tomisfolded protein stress. Cell 115, 727-738. (Pubitemid 38030301)
10. Lee JY, Koga H, Kawaguchi Y, Tang W, Wong E, Gao YS, Pandey UB, Kaushik S, Tresse E, Lu J, Taylor JP, CuervoAM, Yao TP (2010) HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO J 29, 969-980.
11. Ouyang H, Ali YO, Ravichandran M, Dong A, Qiu W, Mackenzie F, Dhe-Paganon S, Arrowsmith CH, Zhai RG (2012) Protein aggregates are recruited to aaggresome by histone deacetylase 6 via unanchored ubiquitin C termini. J Biol Chem 287, 2317-2327.
12. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP (2002) HDAC6 is a microtubule-associated deacetylase. Nature 417, 455-458. (Pubitemid 34563539)
13. Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, Yoshida M, Toft DO, Pratt WB, Yao TP (2005) HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 18, 601-607. (Pubitemid 40726236)
14. Zhang X,Yuan Z, ZhangY,Yong S, Salas-Burgos A,Koomen J, Olashaw N, Parsons JT, Yang XJ, Dent SR, Yao TP, Lane WS, Seto E (2007)HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell 27, 197-213. (Pubitemid 47058299)
15. Parmigiani RB, Xu WS, Venta-Perez G, Erdjument-Bromage H, Yaneva M, Tempst P, Marks PA (2008) HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proc Natl Acad Sci U S A 105, 9633-9638. (Pubitemid 352031352)
16. Subramanian C, Jarzembowski JA, Opipari AWJr, Castle VP, Kwok RP (2011) HDAC6 deacetylates Ku70 and regulates Ku70-Bax binding in neuroblastoma. Neoplasia 13, 726-734.
17. Janke C, Bulinski CJ (2011) Post-translational regulation of the microtubule cytoskeleton: Mechanisms and functions. Nat Rev Mol Cell Biol 12, 773-786.
18. Matsuyama A, Shimazu T, Sumida Y, Saito A, Yoshimatsu Y, Seigneurin-Berny D, Osada H, Komatsu Y, Nishino N, Khochbin S, Horinouchi S, Yoshida M (2002) In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J 21, 6820-6831. (Pubitemid 36014554)
19. Zhang Y, Li N, Caron C, Matthias G, Hess D, Khochbin S, Matthias P (2002) HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J 22, 1168-1179. (Pubitemid 36313600)
20. Bulinski JC (2007) Microtubule modification: Acetylation speeds anterograde traffic flow. Curr Biol 17, R18-R20. (Pubitemid 46027575)
21. Reed NA, Cai D, Blasius TL, Jih GT, Meyhofer E, Gaertig J (2006) Microtubule acetylation promotes kinesin-1 binding and transport. Curr Biol 16, 2166-2172. (Pubitemid 44692098)
22. Dompierre JP, Godin JD, Charrin BC, Cordelieres FP, King SJ, Humbert S, Saudou F (2007) Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by i
23. Chen S, Owens GC, Makarenkova H, Edelman DB (2010) HDAC6 regulates mitochondrial transport in hippocampal neurons. PLoS One 5, e10848.
24. Gao YS, Hubbert CC, Yao TP (2010) The microtubuleassociated histone deacetylase 6 (HDAC6) regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation. J Biol Chem 285, 11219-11226.
25. Aldana-Masangkay GI, Sakamoto KM (2011) The role of HDAC6 in cancer. J Biomed Biotechnol 2011, 875824.
26. Lee JB, Wei J, Liu W, Cheng J, Feng J, Yan Z (2012) Histone deacetylase 6 gates the synaptic action of acute stress in prefrontal cortex. J Physiol 590, 1535-1546.
27. Destaing O, Saltel F, Gilquin B, Chabadel A, Khochbin S, Ory S, Jurdic P (2005) A novel Rho-mDia2-HDAC6 pathway controls podosome patterning through microtubule acetylation in osteoclasts. J Cell Sci 118, 2901-2911. (Pubitemid 41136367)
28. Pandey UB, Batlevi Y, Baehrecke EH, Taylor JP (2007) HDAC6 at the intersection of autophagy, the ubiquitinproteasome system and neurodegeneration. Autophagy 3, 643-645. (Pubitemid 350064219)
29. Kaluza D, Kroll J, Gesierich S, Yao TP, Boon RA, Hergenreider E, Tjwa M, R?ossig L, Seto E, Augustin HG, Zeiher AM, Dimmeler S, Urbich C (2011) Class IIb HDAC6 regulates endothelial cell migration and angiogenesis by deacetylation of cortactin. EMBO J 30, 4142-4156.
30. Sawada M, Sun W, Hayes P, Leskov K, Boothman DA, Matsuyama S (2003) Ku70 suppresses the apoptotic translocation of Bax to mitochondria. Nat Cell Biol 5, 320-329. (Pubitemid 36432296)
31. Kerr E, Holohan C, McLaughlin KM, Majkut J, Dolan S, Redmond K, Riley J, McLaughlin K, Stasik I, Crudden M, Van Schaeybroeck S, Fenning C, O'Connor R, Kiely P, Sgobba M, Haigh D, Johnston PG, Longley DB, Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression andHDACinhibitor-induced apoptosis. Cell Death Differ 19, 1317-1327.
32. Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, Nedelsky NB, Schwartz SL, DiProspero NA, Knight MA, Schuldiner O, Padmanabhan R, Hild M, Berry DL, Garza D, Hubbert CC, Yao TP, Baehrecke EH, Taylor JP (2007) HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 447, 859-863. (Pubitemid 46920134)
33. Boyault C, Gilquin B, Zhang Y, Rybin V, Garman E, Meyer-Klaucke W, Matthias P, M?uller CW, Khochbin S (2006) HDAC6-p97/VCP controlled polyubiquitin chain turnover. EMBO J 25, 3357-3366. (Pubitemid 44141793)
34. Kopito RR (2000) Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 10, 524-530.
35. Boyault C, Sadoul K, Pabion M, Khochbin S (2007) HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene 26, 5468-5476. (Pubitemid 47255928)
36. Vij N (2008) AAA ATPase p97/VCP: Cellular functions, disease and therapeutic potential. J Cell Mol Med 12, 2511-2518.
37. Brush MH, Guardiola A, Connor JH, Yao TP, Shenolikar S (2004) Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases. J Biol Chem 279, 7685-7691. (Pubitemid 38294650)
38. Chen CS, Weng SC, Tseng PH, Lin HP, Chen CS (2005) Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem 280, 38879-38887.
39. Kwon S, ZhangY, Matthias P (2007) The deacetylaseHDAC6 is a novel critical component of stress granules involved in the stress response. Genes Dev 21, 3381-3394.
40. Matthias P, Yoshida M, Khochbin S (2008) HDAC6 a new cellular stress surveillance factor. Cell Cycle 7, 7-10.
41. Serrador JM, Cabrero JR, Sancho D, Mittelbrunn M, Urzainqui A, Śanchez-Madrid F (2004) HDAC6 deacetylase activity links thetubulin cytoskeleton with immune synapse organization. Immunity 20, 417-428. (Pubitemid 38482120)
42. Zhang Y, Kwon S, Yamaguchi T, Cubizolles F, Rousseaux S, Kneissel M, Cao C, Li N, Cheng HL, Chua K, Lombard D, Mizeracki A, Matthias G, Alt FW, Khochbin S, Matthias P (2008) Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol 28, 1688-1701.
43. Beier UH, Akimova T, Liu Y, Wang L, Hancock WW (2011) Histone/protein deacetylases control Foxp3 expression and the heat shock response of T-regulatory cells. Curr Opin Immunol 23, 670-678.
44. Akimova T, Ge G, Golovina T, Mikheeva T,Wang L, Riley JL, Hancock WW (2010) Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. Clin Immunol 136, 348-363.
45. Nam HJ, Kang JK, Kim SK, Ahn KJ, Seok H, Park SJ, Chang JS, Pothoulakis C, Lamont JT, Kim H (2010) Clostridium difficile toxin A decreases acetylation of tubulin, leading to microtubule depolymerization through activation of histone deacetylase 6, and this mediates acute inflammation. J Biol Chem 285, 32888-32896.
46. Kim HJ, Rowe M, Ren M, Hong JS, Chen PS, Chuang DM (2007) Histone deacetylase inhibitors exhibit antiinflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: Multiple mechanisms of action. J Pharmacol Exp Ther 321, 892-901. (Pubitemid 46762687)
47. Zhang B,West EJ, Van KC, Gurkoff GG, Zhou J, Zhang XM, Kozikowski AP, Lyeth BG (2008) HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats. Brain Res 1226, 181-191.
48. Singh J, Khan M, Singh I (2011) HDAC inhibitor SAHA normalizes the levels of VLCFAs in human skin fibroblasts from X-ALD patients and downregulates the expression of proinflammatory cytokines in Abcd1/2-silenced mouse astrocytes. J Lipid Res 52, 2056-2069.
49. Beurel E (2011) HDAC6 regulates LPS-tolerance in astrocytes. PLoS One 6, e25804.
50. Ding H, Dolan PJ, Johnson GV (2008) Histone deacetylase 6 interacts with the microtubule-associated protein tau. J Neurochem 106, 2119-2130.
51. Hempen B, Brion JP (1996) Reduction of acetylated -tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimer's disease. J Neuropathol Exp Neurol 55, 964-972. (Pubitemid 126449410)
52. Perez M, Santa-Maria I, Gomez de Barreda E, Zhu X, Cuadros R, Cabrero JR, Sanchez-Madrid F, Dawson HN, VitekMP, Perry G, Smith MA,Avila J (2009) Tau-an inhibitor of deacetylase HDAC6 function. J Neurochem 109, 1756-1766.
53. Leroy K, Yilmaz Z, Brion JP (2007) Increased level of active GSK-3- in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol Appl Neurobiol 33, 43-55. (Pubitemid 46090309)
54. Rivieccio MA, Brochier C, Willis DE, Walker BA, D'Annibale MA, McLaughlin K, Siddiq A, Kozikowski AP, Jaffrey SR, Twiss JL, Ratan RR, Langley B (2009) HDAC6 is a target for protection and regeneration following injury in the nervous system. Proc Natl Acad Sci U S A 106, 19599-19604.
55. Kilgore M, Miller CA, Fass DM, Hennig KM, Haggarty SJ, Sweatt JD, Rumbaugh G (2010) Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 35, 870-880.
56. d'Ydewalle C, Krishnan J, Chiheb DM,Van Damme P, Irobi J, KozikowskiAP,Vanden Berghe P, TimmermanV, Robberecht W,Van Den Bosch L (2011)HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. Nat Med 17, 968-975.
57. Lasagna-Reeves CA, Castillo-Carranza DL, Guerrero-Muoz MJ, Jackson GR, Kayed R (2010) Preparation and characterization of neurotoxic tau oligomers. Biochemistry 49, 10039-10041.
58. Cook C, Gendron TF, Scheffel K, Carlomagno Y, Dunmore J, Deture M, Petrucelli L (2012) Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulation. Hum Mol Genet 21, 2936-2945.
59. Guthrie CR, KraemerBC(2011) Proteasome inhibition drives HDAC6-dependent recruitment of tau to aggresomes J Mol Neurosci 45, 32-41.
60. Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, Huang EJ, Shen Y, Masliah E, Mukherjee C, Meyers D, Cole PA, Ott M, Gan L (2010) Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 7, 953-966.
61. Cohen TJ, Guo JL, Hurtado DE, Kwong LK, Mills IP, Trojanowski JQ, Lee VM (2011) The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun 2, 252.
62. Irwin DJ, Cohen TJ, Grossman M, Arnold SE, Xie SX, Lee VM, Trojanowski JQ (2012) Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. Brain 135, 807-818.
63. Nguyen D, Alavi MV, Kim KY, Kang T, Scott RT, Noh YH, Lindsey JD,Wissinger B, Ellisman MH,Weinreb RN, Perkins GA, Ju WK (2011) A new vicious cycle involving glutamate excitotoxicity, oxidative stress and mitochondrial dynamics. Cell Death Dis 8, e240.
64. Olney JW, Wozniak DF, Farber NB (1997) Excitotoxic neurodegeneration in Alzheimer disease. New hypothesis and new therapeutic strategies. Arch Neurol 54, 1234-1240. (Pubitemid 27452238)
65. Coyle JT, Puttfarcken P (1993) Oxidative stress, glutamate, and neurodegenerative disorders. Science 262, 689-695. (Pubitemid 23350687)
66. De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, Klein WL (2007) Abeta oligomers induce neuronal oxidative stress through an N-methyl-Daspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 282, 11590-11601. (Pubitemid 47100810)
67. Halili MA, Andrews MR, Labzin LI, Schroder K, Matthias G, Cao C, Lovelace E, Reid RC, Le GT, Hume DA, Irvine KM, Matthias P, Fairlie DP, Sweet MJ (2010) Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS. J Leukoc Biol 87, 1103-1114.
68. Shakespear MR, Halili MA, Irvine KM, Fairlie DP, Sweet MJ (2011) Histone deacetylases as regulators of inflammation and immunity. Trends Immunol 32, 335-343.
69. Shuttleworth SJ, Bailey SG, Townsend PA (2010) Histone deacetylase inhibitors: New promise in the treatment of immune and inflammatory diseases. Curr Drug Targets 11, 1430-1438.
70. Tapia M, Wandosell F, Garrido JJ (2010) Impaired function of HDAC6 slows downaxonal growth and interferes with axon initial segment development. PLoS One 5, e12908.
71. Xie R, Nguyen S, McKeehan WL, Liu L (2010) Acetylated microtubules are required for fusion of autophagosomes with lysosomes. BMC Cell Biol 11, 89.
72. Cardoso SM, Pereira CF, Moreira PI, Arduino DM, Esteves AR, Oliveira CR (2010) Mitochondrial control of autophagiclysosomal pathway in Alzheimer's disease. Exp Neurol 223, 294-298.
73. Lee JY, Nagano Y, Taylor JP, Lim KL, Yao TP (2010) Disease-causing mutations in Parkin impair mitochondrial ubiquitination, aggregation, and HDAC6-dependent mitophagy. J Cell Biol 189, 671-679.
74. Silva DF, Esteves AR, Oliveira CR, Cardoso SM (2011) Mitochondria: The common upstream driver of amyloid-and tau pathology in Alzheimer's disease. Curr Alzheimer Res 8, 563-572.
75. Silva DF, Esteves AR, Arduino DM, Oliveira CR, Cardoso SM (2011) Amyloid- induced mitochondrial dysfunction impairs the autophagic lysosomal pathway in a tubulin dependent pathway. J Alzheimers Dis 26, 565-581.
76. Nixon RA,Yang DS (2011) Autophagy failure in Alzheimer's disease-locating the primary defect. Neurobiol Dis 43, 38-45.
77. Yu WH, Kumar A, Peterhoff C, Shapiro Kulnane L, Uchiyama Y, Lamb BT, Cuervo AM, Nixon RA (2004) Autophagic vacuoles are enriched in amyloid precursor protein-secretase activities: Implications for beta-amyloid peptide over-production and localization in Alzheimer's disease. Int J Biochem Cell Biol 36, 2531-2540. (Pubitemid 39119764)
78. Mizushima N (2005) A- generation in autophagic vacuoles. J Cell Biol 171, 15-17.
79. True O, Matthias P (2012) Interplay between histone deacetylases and autophagy-from cancer therapy to neurodegeneration. Immunol Cell Biol 90, 78-84.
80. Barnett A, Brewer GJ (2011) Autophagy in aging and Alzheimer's disease: Pathologic or protective? J Alzheimer Dis 25, 385-394.
81. Fiesel FC, Schurr C, Weber SS, Kahle PJ (2011) TDP-43 knockdown impairs neurite outgrowth dependent on its target histone deacetylase 6. Mol Neurodegener 6, 64.
82. Fiesel FC, Voigt A, Weber SS, Van den Haute C, Waldenmaier A, G?orner K, Walter M, Anderson ML, Kern JV, Rasse TM, Schmidt T, SpringerW, Kirchner R, Bonin M, Neumann M, Baekelandt V, Alunni-Fabbroni M, Schulz JB, Kahle PJ (2010) Knockdown of transactive response DNAbinding protein (TDP-43) downregulates histone deacetylase 6. EMBO J 29, 209-221.
83. Warraich ST,Yang S, Nicholson GA, Blair IP (2010) TDP-43: A DNA and RNA binding protein with roles in neurodegenerative diseases. Int J Biochem Cell Biol 42, 1606-1609.
84. Ou SH, Wu F, Harrich D, Garćia-Mart́inez LF, Gaynor RB (1995) Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol 69, 3584-3596.
85. Kawahara Y, Mieda-Sato A (2012) TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes. Proc Natl Acad Sci U S A 109, 3347-3352.
86. Gendron TF, Petrucelli L (2011) Rodent models of TDP-43 proteinopathy: Investigating the mechanisms of TDP-43-mediated neurodegeneration. J Mol Neurosci 45, 486-499.
87. Caccamo A, MagŕiA, Oddo S (2010) Age-dependent changes in TDP-43 levels in a mouse model of Alzheimer disease are linked to A- oligomers accumulation. Mol Neurodegener 5, 51.
88. Birdsey GM, Dryden NH, Shah AV, Hannah R, Hall MD, Haskard DO, Parsons M, Mason JC, Zvelebil M, Gottgens B, Ridley AJ, Randi AM (2012) The transcription factor Erg regulates expression of histone deacetylase 6 and multiple pathways involved in endothelial cell migration and angiogenesis. Blood 119, 894-903.
89. Poulin SP, Dautoff R, Morris JC, Barrett LF, Dickerson BC (2011) Amygdala atrophy is prominent in early Alzheimer's disease and relates to symptom severity. Psychiatry Res 194, 7-13.
90. Bedrosian TA, Herring KL, Weil ZM, Nelson RJ (2011) Altered temporal patterns of anxiety in aged and amyloid precursor protein (APP) transgenic mice. Proc Natl Acad Sci U S A 108, 11686-11691.
91. Youn JC, Lee DY, Jhoo JH, KimKW, Choo IH,Woo JI (2011) Prevalence of neuropsychiatric syndromes in Alzheimer's disease (AD). Arch Gerontol Geriatr 52, 258-263.
92. Fukada M, Hanai A, Nakayama A, Suzuki T, Miyata N, Rodriguiz RM, Wetsel WC, Yao TP, Kawaguchi Y (2012) Loss of deacetylation activity of Hdac6 affects emotional behavior in mice. PLoS One 7, e30924.
93. Espallergues J, Teegarden SL, Veerakumar A, Boulden J, Challis C, Jochems J, Chan M, Petersen T, Deneris E, Matthias P, Hahn CG, Lucki I, Beck SG, Berton O (2012) HDAC6 regulates glucocorticoid receptor signaling in serotonin pathways with critical impact on stress resilience. J Neurosci 32, 4400-4416.
94. Xu K, Dai XL, Huang HC, Jiang ZF (2011) TargetingHDACs: A promising therapy for Alzheimer's Disease. Oxid Med Cell Longev 2011, 143269.
95. Kazantsev AG, Thompson LM (2008) Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov 7, 854-868.
96. Francis YI, Fà M, Ashraf H, Zhang H, Staniszewski A, Latchman DS, Arancio O (2009) Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's disease J Alzheimers Dis 18, 131-139.